Drugs / Satoreotide trizoxetan
Satoreotide trizoxetan
also known as
68Ga-IPN01070 · 68Ga-OPS202 · 68Ga-satoreotide trizoxetan · JR-11-NODAGA · NODAGA-JR11 · OPS-202 · Satoreotida trizoxetan
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03773133 | May → Oct 2019 | small cell lung carcinoma | Ipsen | Terminated | No outcome recorded |
| Phase 1/2 | NCT02162446 | Jun 2014 → Jun 2015 | digestive system neuroendocrine neoplasm | Ipsen | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03697551 | Oct 2018 → Feb 2019 | breast cancer | Ipsen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03220217 | Sep 2017 → Jul 2019 | digestive system neuroendocrine neoplasm | Ipsen | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | satoreotide trizoxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02162446 ↗ |
| Known as | 68Ga-IPN01070 | “The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to...” NCT03220217 ↗ |
| Known as | 68Ga-OPS202 | “The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to...” NCT03220217 ↗ |
| Known as | 68Ga-satoreotide trizoxetan | “The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to...” NCT03220217 ↗ |
| Known as | JR-11-NODAGA | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297532 ↗ |
| Known as | NODAGA-JR11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297532 ↗ |
| Known as | OPS-202 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297532 ↗ |
| Known as | Satoreotida trizoxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297532 ↗ |
| Modality | Diagnostic / imaging agent | “Positron emission tomography (PET) imaging agent” NCT03220217 ↗ |
| Route | Intravenous | “first intravenous (i.v.) injection of satoreotide trizoxetan” NCT03220217 ↗ |